239 related articles for article (PubMed ID: 30252199)
1. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
[TBL] [Abstract][Full Text] [Related]
2. Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition.
Tamura N; Ishiguro C; Matsuda T
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):166-75. PubMed ID: 24737526
[TBL] [Abstract][Full Text] [Related]
3. Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post-approval in Japan.
Saito R; Miyazaki S
Pharmacol Res Perspect; 2023 Aug; 11(4):e01110. PubMed ID: 37365794
[TBL] [Abstract][Full Text] [Related]
4. Streamlining Considerations for Safety Measures: A Predictive Model for Addition of Clinically Significant Adverse Reactions to Japanese Drug Package Inserts.
Watanabe T; Ambe K; Tohkin M
Biol Pharm Bull; 2024; 47(3):611-619. PubMed ID: 38479885
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
6. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
Hirota S; Yamaguchi T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
[TBL] [Abstract][Full Text] [Related]
7. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
Ishiguro C; Misu T; Iwasa E; Izawa T
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
[TBL] [Abstract][Full Text] [Related]
8. Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
Pacurariu AC; Hoeve CE; Arlett P; Genov G; Slattery J; Sturkenboom MCJM; Straus SMJM
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):168-173. PubMed ID: 29278866
[TBL] [Abstract][Full Text] [Related]
9. Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model.
Watanabe T; Ambe K; Tohkin M
Ther Innov Regul Sci; 2024 Mar; 58(2):357-367. PubMed ID: 38135862
[TBL] [Abstract][Full Text] [Related]
10. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
11. An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance.
Pinheiro LC; Candore G; Zaccaria C; Slattery J; Arlett P
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):38-45. PubMed ID: 29143393
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
[TBL] [Abstract][Full Text] [Related]
13. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks.
Bloem LT; Karomi M; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Mantel-Teeuwisse AK
Expert Opin Drug Saf; 2021 Nov; 20(11):1433-1442. PubMed ID: 34263667
[No Abstract] [Full Text] [Related]
15. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
[TBL] [Abstract][Full Text] [Related]
16. Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries.
Tham MY; Ye Q; Ang PS; Fan LY; Yoon D; Park RW; Ling ZJ; Yip JW; Tai BC; Evans SJ; Sung C
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):87-94. PubMed ID: 29108136
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
18. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
19. Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
Nakayama H; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Feb; 33(1):45-52. PubMed ID: 31933266
[TBL] [Abstract][Full Text] [Related]
20. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
Li X; Lin X; Ren H; Guo J
J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
